Stanford Medicine and LEADOPTIK Announce Research Collaboration to Advance AI-Enhanced, Real-Time Optical Imaging in Lung Cancer Biopsy
LEADOPTIK Inc., a Silicon Valley-based medical imaging company, has partnered with Stanford Medicine for a research collaboration. The collaboration aims to investigate the potential of AI-enhanced real-time optical imaging for lung biopsy procedures. This partnership highlights the growing significance of AI technology in the medical field. The research could lead to advancements in diagnostic and treatment procedures for lung-related conditions. The collaboration reflects a commitment to innovation and improving healthcare outcomes.
SAN JOSE, Calif., March 19, 2025 – LEADOPTIK Inc., a Silicon Valley-based medical imaging company, announced a research collaboration with Stanford Medicine to explore AI-enhanced real-time optical imaging in lung biopsy procedures. This partnership aims to improve lesion assessment, biopsy accuracy, and support clinical decision-making in the context of lung cancer diagnosis.
Research Collaboration for Lung Biopsy Procedures
Lung cancer is a leading cause of cancer-related deaths globally, highlighting the crucial role of early detection and intervention in improving survival rates. The challenge lies in diagnosing small lung nodules effectively, often resulting in inconclusive biopsies and treatment delays.
The collaboration between LEADOPTIK and Stanford Medicine seeks to integrate real-time optical imaging into biopsy workflows to provide immediate insights for physicians at the point of care. This initiative aims to enhance diagnostic precision and lay the groundwork for more intelligent, image-guided decision-making processes.
Stanford Medicine's Role
Stanford Medicine's Interventional Pulmonology Program will lead the evaluation of this technology for lung biopsy procedures. Leveraging their expertise in minimally invasive pulmonary diagnostics, Stanford will assess how high-resolution imaging and AI-powered interpretation can enhance sample collection strategies and improve patient outcomes.
Dr. Harmeet Bedi, Director of Interventional Pulmonology at Stanford Medicine, expressed the institution's commitment to evaluating transformative technologies that can enhance patient care. Dr. Brian Shaller, Clinical Assistant Professor and Program Director of the IP Fellowship, emphasized the potential of real-time optical imaging in refining diagnostic strategies and optimizing tissue sampling.
LEADOPTIK's Technology
LEADOPTIK specializes in real-time optical imaging for interventional procedures, providing high-resolution visualization directly to physicians. The data collected through this collaboration will help enhance the application of advanced analytics, further supporting the adoption of intelligent imaging solutions in clinical practice.
Reza Khorasaninejad, CEO of LEADOPTIK, highlighted the importance of this partnership in validating their imaging technology and exploring how advanced image analysis can improve the precision of lung biopsy procedures.
Advancing Healthcare Innovation
This collaboration underscores Silicon Valley's role as a hub for medical innovation, where academic institutions and startups collaborate to bring transformative healthcare solutions to patients. Stanford Medicine's expertise in biomedical research, patient care, and medical education, combined with LEADOPTIK's cutting-edge imaging technology, aims to revolutionize lung cancer diagnostics and treatment.
Media Contact: [email protected]
SOURCE: LEADOPTIK